Every 10-Q that Bioventus Inc. (BVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BVS filings page.
Bioventus Inc. reported stronger quarterly results, returning to profitability. Net sales rose to $132.1 million, up 6.6% year over year, driven by growth in Pain Treatments and Surgical Solutions in both U.S. and international markets.
The company generated net income of $3.9 million versus a $3.3 million loss a year ago, with diluted EPS of $0.04. Gross margin improved to 68.7%, and Adjusted EBITDA increased to $23.9 million from $19.2 million.
Operating cash flow improved to $8.9 million, enabling a discretionary $22.0 million prepayment on the 2025 Term Loan. The term loan balance was $274.3 million before discounts, and cash and cash equivalents were $35.8 million. The company remained in compliance with its credit covenants.
Bioventus Inc. (BVS) reported Q3 2025 results. Net sales were $138.651 million, essentially flat year over year. Operating income improved to $11.252 million from $3.647 million, and net income attributable to Bioventus was $3.155 million (diluted EPS $0.05) versus a loss of $5.165 million (diluted EPS $(0.08)) a year ago.
For the first nine months, net sales were $410.187 million and net income attributable to Bioventus was $7.977 million (diluted EPS $0.12) versus a loss of $35.737 million (diluted EPS $(0.56)) last year. Cash from operating activities rose to $36.705 million; cash ended at $42.164 million.
The company refinanced its debt on July 31, 2025 with a new $300 million term loan and a $100 million revolver maturing in 2030. As of quarter end, $25 million was drawn on the revolver, with $75 million available, and Bioventus was in compliance with covenants. It entered interest rate swaps covering $150 million notional at a weighted average fixed rate of 3.60%, recognized as a $785 thousand loss in AOCI. The company paid $19.771 million of Bioness contingent consideration and recorded no further Bioness obligations. Bioventus also recorded an immaterial revision to 2024 equity-based compensation, adjusting prior-period figures.